Previous 10 | Next 10 |
2024-03-06 08:45:57 ET More on Mid-day gainers & stocks. Dada Nexus Rides Closer To JD.com's Orbit With Management Shakeup Infobird to effect 1-for-8 reverse stock split to regain compliance with Nasdaq rules NIO, Dada Nexus and Luckin Coffee lead strong recovery...
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $...
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public offering of 16,700,000 shares of its common stock at a public offering price of $4....
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. Absci also intends ...
2024-02-22 14:41:34 ET More on Amgen, Eli Lilly, etc. Pfizer's Post-Pandemic Pivot Pfizer: Turnaround Is Gaining Momentum Eli Lilly: Yes, It Is Too Late To Join The Party Novo to face Wegovy competition in India as local versions loom: Reuters Weight-...
2024-02-21 07:46:16 ET More on Absci Absci hits new 52-week high as race for AI drug discovery heats up KeyBanc sees opportunity in tech-enabled drug discovery stocks Seeking Alpha’s Quant Rating on Absci Historical earnings data for Absci Fina...
VANCOUVER, Wash. and NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using Absci’s de ...
Sir Pangalos is a distinguished biopharmaceutical executive who led BioPharmaceuticals R&D at AstraZeneca. In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board. VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (N...
Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash. and NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generati...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
News, Short Squeeze, Breakout and More Instantly...
Absci Corporation Company Name:
ABSI Stock Symbol:
NASDAQ Market:
Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today re...
VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, M...
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during T...